The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10828 malaria professionals are enjoying the free benefits of MalariaWorld today

resistant

Ecology of asynchronous asexual replication: the intraerythrocytic development cycle of Plasmodium berghei is resistant to host rhythms

February 23, 2021 - 14:14 -- Open Access
Author(s): 
Aidan J. O’Donnell and Sarah E. Reece
Reference: 
Malaria Journal 2021 20:105, 19 February 2021

Daily periodicity in the diverse activities of parasites occurs across a broad taxonomic range. The rhythms exhibited by parasites are thought to be adaptations that allow parasites to cope with, or exploit, the consequences of host activities that follow daily rhythms. Malaria parasites (Plasmodium) are well-known for their synchronized cycles of replication within host red blood cells. Whilst most species of Plasmodium appear sensitive to the timing of the daily rhythms of hosts, and even vectors, some species present no detectable rhythms in blood-stage replication. Why the intraerythrocytic development cycle (IDC) of, for example Plasmodium chabaudi, is governed by host rhythms, yet seems completely independent of host rhythms in Plasmodium berghei, another rodent malaria species, is mysterious.

Chemoprotective Antimalarial Activity of P218 against Plasmodium falciparum: A Randomized, Placebo-Controlled Volunteer Infection Study

February 10, 2021 - 09:44 -- Open Access
Author(s): 
Chughlay MF, El Gaaloul M, Chalon S, et al.
Reference: 
Am J Trop Med Hyg. 2021 Feb 8:tpmd201165

P218 is a highly selective dihydrofolate reductase inhibitor with potent in vitro activity against pyrimethamine-resistant Plasmodium falciparum. This single-center, randomized, double-blind, placebo-controlled phase Ib study evaluated P218 safety and chemoprotective efficacy in a P. falciparum sporozoite (PfSPZ) volunteer infection study (VIS). Consecutive dose safety and tolerability were evaluated (cohort 1), with participants receiving two oral doses of P218 1,000 mg 48 hours apart (n = 6), or placebo (n = 2). P218 chemoprotective efficacy was assessed (cohorts 2 and 3) with direct venous inoculation of 3,200 aseptic, cryopreserved PfSPZ (NF54 strain) followed 2 hours later with two P218 doses of 1,000 mg (cohort 2, n = 9) or 100 mg (cohort 3, n = 9) administered 48 hours apart, or placebo (n = 6).

Efficient population modification gene-drive rescue system in the malaria mosquito Anopheles stephensi

November 4, 2020 - 15:20 -- Open Access
Author(s): 
Adolfi A, Gantz VM, James AA, et al.
Reference: 
Nat Commun. 2020 Nov 3;11(1):5553

Cas9/gRNA-mediated gene-drive systems have advanced development of genetic technologies for controlling vector-borne pathogen transmission. These technologies include population suppression approaches, genetic analogs of insecticidal techniques that reduce the number of insect vectors, and population modification (replacement/alteration) approaches, which interfere with competence to transmit pathogens.

NOT Open Access | Mice chronically fed a high-fat diet are resistant to malaria induced by Plasmodium berghei ANKA

October 1, 2019 - 14:33 -- NOT Open Access
Author(s): 
Onésia Cristina Oliveira-Lima, Natália Lourenço Almeida, Camila Megale Almeida-Leite & Juliana Carvalho-Tavares
Reference: 
Parasitology Research, October 2019, Volume 118, Issue 10, pp 2969–2977

C57BL/6 mice infected with Plasmodium berghei ANKA (PbA) develop neurological symptoms and die 6-–7-day post-inoculation in the absence of high parasitemia.

Medical Condition: 
Subscribe to RSS - resistant